Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

Clinical Trial ID NCT02028403

Rank	Title	Journal	Year	PubWeight™‹?›
1	Eradicating HIV-1 infection: seeking to clear a persistent pathogen.	Nat Rev Microbiol	2014	1.65
2	Immune checkpoint inhibitors in clinical trials.	Chin J Cancer	2014	0.98
3	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.	Int J Mol Sci	2016	0.97
4	Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy.	Open AIDS J	2014	0.83
5	PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.	Case Rep Oncol Med	2015	0.83
6	A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.	Clin Transl Immunology	2016	0.82
7	Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents.	Open Forum Infect Dis	2016	0.80
8	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.	Therap Adv Gastroenterol	2016	0.78
9	Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.	Drugs	2015	0.77
10	Viral Manipulation of Host Inhibitory Receptor Signaling for Immune Evasion.	PLoS Pathog	2016	0.77